These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 1824849)

  • 21. Activation of human cytolytic cells through CD2/T11. Comparison of the requirements for the induction and direction of lysis of tumor targets by T cells and NK cells.
    Scott CF; Bolender S; McIntyre GD; Holldack J; Lambert JM; Venkatesh YP; Morimoto C; Ritz J; Schlossman SF
    J Immunol; 1989 Jun; 142(11):4105-12. PubMed ID: 2565930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention.
    Franciszkiewicz K; Le Floc'h A; Jalil A; Vigant F; Robert T; Vergnon I; Mackiewicz A; Benihoud K; Validire P; Chouaib S; Combadière C; Mami-Chouaib F
    Cancer Res; 2009 Aug; 69(15):6249-55. PubMed ID: 19638592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.
    Scott CF; Blättler WA; Lambert JM; Kalish RS; Morimoto C; Schlossman SF
    J Clin Invest; 1988 May; 81(5):1427-33. PubMed ID: 2966815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function.
    Gati A; Guerra N; Giron-Michel J; Azzarone B; Angevin E; Moretta A; Chouaib S; Caignard A
    Cancer Res; 2001 Apr; 61(8):3240-4. PubMed ID: 11309272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS; Hargrove ME; Ting CC
    Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth.
    Qian JH; Titus JA; Andrew SM; Mezzanzanica D; Garrido MA; Wunderlich JR; Segal DM
    J Immunol; 1991 May; 146(9):3250-6. PubMed ID: 1826709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
    Moritz D; Groner B
    Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
    Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM
    Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma.
    Mackensen A; Ferradini L; Carcelain G; Triebel F; Faure F; Viel S; Hercend T
    Cancer Res; 1993 Aug; 53(15):3569-73. PubMed ID: 8339262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI; Nelson H; Thibault C
    J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen.
    Phillips JH; Lanier LL
    J Immunol; 1986 Mar; 136(5):1579-85. PubMed ID: 2419407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clonal heterogeneity in LFA-3 and ICAM-1 requirement for lysis by alloreactive T lymphocytes.
    Galocha B; López D; López de Castro JA
    J Immunol; 1993 Mar; 150(5):1653-62. PubMed ID: 7679690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor.
    Bolhuis RL; Roozemond RC; van de Griend RJ
    J Immunol; 1986 Jun; 136(11):3939-44. PubMed ID: 3084649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells.
    Liu MA; Nussbaum SR; Eisen HN
    Science; 1988 Jan; 239(4838):395-8. PubMed ID: 3257303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.
    Pupa SM; Canevari S; Fontanelli R; Ménard S; Mezzanzanica D; Lanzavecchia A; Colnaghi MI
    Int J Cancer; 1988 Sep; 42(3):455-9. PubMed ID: 2971021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo.
    Novak H; Noy R; Oved K; Segal D; Wels WS; Reiter Y
    Int J Cancer; 2007 Jan; 120(2):329-36. PubMed ID: 17066453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.
    Nijhuis EW; vd Wiel-van Kemenade E; Figdor CG; van Lier RA
    Cancer Immunol Immunother; 1990; 32(4):245-50. PubMed ID: 2175673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis.
    Kranz DM; Patrick TA; Brigle KE; Spinella MJ; Roy EJ
    Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9057-61. PubMed ID: 7568072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An in-vitro model for tumor immunotherapy with antibody heteroconjugates.
    Jung G; Eberhard HJ
    Immunol Today; 1988 Sep; 9(9):257-60. PubMed ID: 2978374
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.